Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancer indications, is the company's biggest ...

All attendees shared a vested interest in the rapidly evolving cancer treatment landscape. Nowhere was the vastness of that ...

From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...